Expertise in
21
conditions

Dr. Sherif Farag

Hematology
Community Howard Regional Health
3500 S Lafountain St, 
Kokomo, IN 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
36 Years of Experience
Expertise in
21
conditions
Community Howard Regional Health
3500 S Lafountain St, 
Kokomo, IN 

Overview

Sherif Farag is a Hematologist practicing medicine in Kokomo, Indiana. He has been practicing medicine for over 36 years.

Dr. Farag is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in IN

Hospital Affiliations

Community Howard Regional Health Inc.
Community Hospital North
Community Hospital Of Anderson And Madison County
Community Hospital East

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Community Howard Regional Health
3500 S Lafountain St, Kokomo, IN 46902

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological
Study Phase: Phase 2
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 2
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CD24Fc, Methotrexate, Tacrolimus
Study Phase: Phase 3
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Biological
Study Drug: Neihulizumab (AbGn-168H)
Study Phase: Phase 1
A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: February 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
Enrollment Status: Completed
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

55 Total Publications

Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research and Organ Procurement and Transplantation Network Study.
Risk Factors for Solid Organ Graft Failure and Death in Hematopoietic Cell Transplant Recipients Undergoing Solid Organ Transplantation: A Retrospective Center for International Blood and Marrow Transplant Research and Organ Procurement and Transplantation Network Study.
Journal: Transplantation
Published: June 23, 2025
Similar Doctors
Expertise in
6
conditions
Dr. Amy Shapiro
Hematology | Oncology
Expertise in
6
conditions
Dr. Amy Shapiro
Hematology | Oncology
Referral may be required

Indiana Hemophilia And Thrombosis Center Inc

8326 Naab Rd, 
Indianapolis, IN 
 (37.5 miles away)
317-871-0000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amy Shapiro is a Hematologist and an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shapiro is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Hemophilia B, and Ligneous Conjunctivitis.

Expertise in
24
conditions
Dr. Nabil Adra
Hematology
Expertise in
24
conditions
Dr. Nabil Adra
Hematology
Referral may be required

Univ. Radiation Oncology Associates Inc.

535 Barnhill Dr, 
Indianapolis, IN 
 (46.5 miles away)
317-944-0920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nabil Adra is a Hematologist practicing medicine in Indianapolis, Indiana. Dr. Adra is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Teratoma of the Mediastinum, Prostate Cancer, Orchiectomy, and Bone Marrow Transplant.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Community Howard Regional Health

3500 S Lafountain St, 
Kokomo, IN 
 (0.1 miles away)
765-776-3500
Languages Spoken:
English
See accepted insurances

Mohammad Abu Zaid is a Hematologist practicing medicine in Kokomo, Indiana. Dr. Abu Zaid is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Sherif Farag

How do I make an appointment with Dr. Sherif Farag?

You can book an appointment with Dr. Sherif Farag by calling their office at 765-776-3500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sherif Farag a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sherif Farag is classified as an Distinguished expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sherif Farag specialize in?

While Dr. Sherif Farag is a Hematology, they have specific expertise in Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sherif Farag participate in research or clinical trials?

Yes. Dr. Sherif Farag has published 55 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Sherif Farag's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sherif Farag accept my insurance?

Dr. Sherif Farag accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 765-776-3500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Farag's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 14 Advanced Conditions
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile